Cajal Neuroscience launches with $96M Series A, tackling Alzheimer's and Parkinson's
Cajal Neuroscience has emerged with a $96 million Series A and plans to discover drug candidates in Alzheimer’s and Parkinson’s with a wealth of gene data.
Cajal, named after Spanish neuroscientist Santiago Ramón y Cajal, was founded by Ian Peikon and Andrew Dervan around two years ago out of the Lux Capital offices in New York City, but the duo quickly decided to move the company across the US to Seattle due to the institutions in the area having more neuroscience expertise. After the move out west, Peikon told Endpoints News the company quickly started looking for new targets in neurodegenerative diseases and has also grown to around 55 employees.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.